2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
about
Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerLow EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.A critical review of recent developments in radiotherapy for non-small cell lung cancerLung cancer in Brazil: epidemiology and treatment challenges.Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.Making Meaningful Clinical Use of BiomarkersIn- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy.A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic reviewProlonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMTCAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype.Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients wBevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases.Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial.Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.What are the options for non-small-cell lung cancer patients post second-line therapy?Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma.Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials.From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells.The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patientsSelective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regressionPhase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
P2860
Q26784298-CDB66A13-2E47-484F-B500-908CF298B1B2Q26995204-F905BE19-22A0-45BA-BAA7-16BFBE2C913FQ27002509-DA4995E4-F283-4853-BFC6-F6BF8292B6AAQ27853221-0A0145DA-676B-45C0-A795-C3EBE19774C6Q28079625-22BF1CEC-793B-4AED-B384-D84412882351Q30235908-931033F5-EFB1-430B-A667-09BB48602C08Q33427359-F9A2AA89-292A-443A-B592-ACF22CE73E59Q33437650-0AB3EBEB-9505-478D-8A04-C9855E3FDD17Q33639335-C6C4952F-6674-42DA-B652-4090E9E1656DQ33821481-464F985B-DC36-443A-891A-1F19CC0C7C8FQ33865965-3C1438B7-C1B5-407C-8921-624C194F0EDFQ33868401-0FB0C11A-E5B3-43E9-AAEF-CDBAD8508A99Q34479081-0D2383AE-7228-4D4B-A5DA-E556701686ACQ34663877-9B19CD12-59B5-4A2B-BA31-F0BE0CE9AC93Q34742887-5146E3A3-E23E-4252-946F-425C7C9A92A1Q35928957-172976D0-D872-46AF-AE0D-4E530D4FE42BQ36557389-2C7725EE-9849-417A-8B6D-FEDBFF6A1D7BQ36782414-2095CF44-8195-4D17-9A73-33CC8778D76FQ37123936-19C6D43D-7E8B-485F-9691-BA04A1EAD3BAQ37581974-77268FD3-3313-410C-B778-71218B0DF11EQ37669505-02296D07-97F9-4A09-8B9D-450DFCE90D00Q37731321-6521683A-C665-4CE8-8311-20F54F502A50Q38564088-B6B9508A-56E4-42F6-95C8-B19C74E5CF5EQ38565868-EF6397D0-CB42-41A3-93A3-48D84DB35001Q38601725-4CAC82BD-81BF-4EF1-AC5B-06AF5F23AA15Q38611422-03922E68-71EA-4547-B3C3-8CD5622CD4BFQ38673153-39F0E693-DD74-44D0-87CD-5D768710112AQ38711948-2534B8FA-9B16-4F41-8EA4-BB0A741CA8DBQ38815297-E5EE3A97-16D3-4CC1-BD71-6AE109E082CAQ38990822-D55A8371-62D8-46F2-BB45-CBED84398CDDQ39041541-E18E6050-1049-43B8-B0C2-421122DF84DDQ39835396-844C898F-D019-40B8-A5D6-7C8A5360E0B9Q40562646-890B44E0-89ED-4591-A4CE-E3E404362469Q41011322-65E33080-C6AD-4C4D-BD04-6DF765FBAB98Q41149149-B5E6418C-2D61-490F-9DE2-6FA6A7B91661Q41340872-27D8E068-7B36-4940-BA40-FADF284DD751Q41511092-EB5C4DF1-73C8-4A64-95CE-B573D5F08B2EQ41595459-0B22BDA0-44ED-43ED-8FD8-BA969F65773CQ41831075-8DB7F54A-6AE6-44AA-BD0E-C11DC0227DE2Q42290027-A5DD3301-67CC-461C-A78C-DA9B4C2F0288
P2860
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
2nd ESMO Consensus Conference ...... treatment in advanced disease.
@en
type
label
2nd ESMO Consensus Conference ...... treatment in advanced disease.
@en
prefLabel
2nd ESMO Consensus Conference ...... treatment in advanced disease.
@en
P2093
P2860
P356
P1433
P1476
2nd ESMO Consensus Conference ...... treatment in advanced disease.
@en
P2093
L Paz-Ares
M Nicolson
P2860
P304
P356
10.1093/ANNONC/MDU123
P577
2014-03-25T00:00:00Z